According to Takeda Pharmaceutical's latest financial reports the company has $2.54 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-03-31 | $4.15 B | -42.03% |
2022-03-31 | $7.17 B | -21.12% |
2021-03-31 | $9.09 B | 50.31% |
2020-03-31 | $6.04 B | -7.45% |
2019-03-31 | $6.53 B | 85.19% |
2018-03-31 | $3.52 B | 4.87% |
2017-03-31 | $3.36 B | -32.48% |
2016-03-31 | $4.98 B | -16.16% |
2015-03-31 | $5.94 B | -28.13% |
2014-03-31 | $8.27 B | 42.38% |
2013-03-31 | $5.80 B | 5.66% |
2012-03-31 | $5.49 B | -47.71% |
2011-03-31 | $10.51 B | 11.33% |
2010-03-31 | $9.44 B | 23.18% |
2009-03-31 | $7.66 B | -54.57% |
2008-03-31 | $16.87 B | 10.41% |
2007-03-31 | $15.28 B | -3.72% |
2006-03-31 | $15.87 B | 11.75% |
2005-03-31 | $14.20 B | 12.35% |
2004-03-31 | $12.64 B | 30.74% |
2003-03-31 | $9.67 B | 36.99% |
2002-03-31 | $7.06 B | 23.59% |
2001-03-31 | $5.71 B |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | $24.61 B | 866.74% | ๐บ๐ธ USA |
![]() Novartis NVS | $11.17 B | 338.89% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | $19.97 B | 684.45% | ๐บ๐ธ USA |
![]() Amgen AMGN | $34.24 B | 1,245.17% | ๐บ๐ธ USA |
![]() Sanofi SNY | $8.68 B | 241.20% | ๐ซ๐ท France |
![]() Merck MRK | $10.38 B | 307.97% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | $8.20 B | 222.25% | ๐ฌ๐ง UK |
![]() Seagen
SGEN | $1.29 B | -49.25% | ๐บ๐ธ USA |
![]() Dr. Reddy's RDY | $0.74 B | -70.73% | ๐ฎ๐ณ India |